Degradation of the TEAD-YAP/TAZ Transcription Factor Complex by Heterobifunctional Small Molecules that Bind to the TEAD Allosteric Lipid Pocket
Yeh, I.-J.; Ghozayel, M.; Bum-Erdene, K.; Meroueh, S.
Show abstract
Central kinases of the Hippo tumor suppressor pathway phosphorylate the transcriptional coactivators YAP and TAZ to sequester them in the cytoplasm. In cancer, Hippo pathway kinases have reduced activity, leading to translocation of YAP and TAZ into the nucleus where they engage TEADs and other transcription factors. Here, we explore whether heterobifunctional small molecules that bind to the TEAD allosteric lipid-binding pocket can degrade the TEAD*YAP/TAZ complex. We design and synthesize heterobifunctional molecules that consist of flufenamic acid analogs that bind to the allosteric TEAD lipid pocket, a long and flexible linker, and thalidomide to engage E3 ubiquitin ligase component cereblon. The bifunctional compounds promote ternary complex formation in biochemical assays and mammalian cells but exhibited modest degradation of TEAD, YAP, and TAZ in cancer cells. Methyl ester analogs of these compounds led to substantial proteasomal degradation of the TEAD*YAP/TAZ complex in cancer cells. This work provides a strategy for depletion of nuclear YAP and TAZ and for exploration of their TEAD-dependent and TEAD-independent activities in vivo.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Morphological Subprofile Analysis for Bioactivity Annotation of Small Molecules 94%
- Discovery of an AKT Degrader with Prolonged Inhibition ofDownstream Signaling 94%
- A direct high-throughput protein quantification strategy facilitates discovery and characterization of a celastrol-derived BRD4 degrader 93%
Similar papers in this journal
- Temporal and Spatial Characterization of CUL3KLHL20-driven Targeted Degradation of BET family, BRD Proteins by the Macrocycle-based Degrader BTR2004 95%
- Repurposing of the RIPK1 selective benzooxazepin-4-one scaffold for the development of a type-III LIMK1/2 inhibitor 95%
- Small Molecule Activation of NAPE-PLD Enhances Efferocytosis by Macrophages 95%
Similar papers in this journal
- Development of a novel high-throughput screen for the identification of new inhibitors of protein S-acylation 95%
- Development of FERM domain protein-protein interaction inhibitors for MSN and CD44 as a potential therapeutic strategy for Alzheimer's disease. 95%
- Covalent inhibition of the SARS-CoV-2 NiRAN domain via an active-site cysteine 95%
Similar papers in this journal
- PKIS Deep Dive Yields a Chemical Starting Point for Dark Kinases and a Cell Active BRSK2 Inhibitor 95%
- A screen of FDA-approved drugs identifies inhibitors of Protein Tyrosine Phosphatase 4A3 (PTP4A3 or PRL-3) 95%
- HTRF-based identification of small molecules targeting SARS-CoV-2 E protein interaction with ZO-1 PDZ2 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.